These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 30536746)

  • 1. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
    Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
    J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
    J Diabetes Investig; 2021 Feb; 12(2):200-206. PubMed ID: 32623839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
    Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
    J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study.
    Tobe K; Maegawa H; Tabuchi H; Nakamura I; Uno S
    J Diabetes Investig; 2019 Sep; 10(5):1262-1271. PubMed ID: 30719865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
    Kaku K; Isaka H; Sakatani T; Toyoshima J
    J Diabetes Investig; 2020 May; 11(3):662-671. PubMed ID: 31743569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
    Miura H; Sakaguchi K; Okada Y; Yamada T; Otowa-Suematsu N; So A; Komada H; Hirota Y; Ohara T; Kuroki Y; Hara K; Matsuda T; Kishi M; Takeda A; Yokota K; Tamori Y; Ogawa W
    J Diabetes Investig; 2019 Sep; 10(5):1254-1261. PubMed ID: 30688412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
    Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
    J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
    Takahashi K; Cho KY; Nakamura A; Miya A; Miyoshi A; Yamamoto C; Nomoto H; Niwa H; Takahashi K; Manda N; Kurihara Y; Aoki S; Ito YM; Atsumi T; Miyoshi H
    J Diabetes Investig; 2019 Mar; 10(2):429-438. PubMed ID: 30136403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study.
    Nakaguchi H; Kondo Y; Kyohara M; Konishi H; Oiwa K; Terauchi Y
    J Diabetes Investig; 2020 Nov; 11(6):1542-1550. PubMed ID: 32279451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
    Ishihara H; Yamaguchi S; Nakao I; Okitsu A; Asahina S
    Diabetes Obes Metab; 2016 Dec; 18(12):1207-1216. PubMed ID: 27436788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
    Hwang YC; Kim JH; Lee BW; Lee WJ
    Diabetes Metab J; 2019 Dec; 43(6):898-905. PubMed ID: 31237132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
    Nagai Y; Ohta A; Sada Y; Kato H; Tanaka Y
    Expert Opin Pharmacother; 2017 Jan; 18(1):13-17. PubMed ID: 27841020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
    Terauchi Y; Fujiwara H; Kurihara Y; Suganami H; Tamura M; Senda M; Gunji R; Kaku K
    J Diabetes Investig; 2019 Nov; 10(6):1518-1526. PubMed ID: 31033218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD.
    Ito D; Shimizu S; Haisa A; Yanagisawa S; Inoue K; Saito D; Sumita T; Yanagisawa M; Uchida Y; Inukai K; Shimada A
    J Diabetes Investig; 2024 Sep; 15(9):1220-1230. PubMed ID: 38775319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
    Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
    Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Fujiwara H; Kaku K
    J Diabetes Investig; 2019 Sep; 10(5):1272-1283. PubMed ID: 30702214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
    Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
    Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.